Lila Levinson, PhD,  Science Writer—

Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.

Articles by Lila Levinson, PhD

Patients pick Medtronic adaptive DBS over traditional technology

Parkinson’s disease patients in a clinical trial preferred Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) technology — which automatically adjusts stimulation in response to brain signals — to traditional continuous DBS therapy. The ADAPT-PD (NCT04547712) study also found that BrainSense was safe and effective, and that it…

Oncodesign joins MJFF LRRK2 development collaboration

Oncodesign Precision Medicine (OPM) joined a Michael J. Fox Foundation (MJFF) program to develop potential therapies that target the LRRK2 protein, a key contributor to some forms of Parkinson’s disease. “Our mission has always been to put patients at the center of our innovation,” Jan Hoflack, PhD, OPM’s…

Scientists may have found way to prevent constipation in Parkinson’s

Interactions between receptors for ghrelin, the so-called hunger hormone, and the chemical signaling molecule dopamine may go awry in Parkinson’s disease, potentially leading to chronic constipation — a symptom that the Australian scientists behind this new research called “debilitating” for many people with the condition. To learn more about…

Experts push for ways to expand Parkinson’s specialist care

A new study suggests that simple, targeted strategies, from using telehealth to standardizing patient referrals, could help more people with Parkinson’s disease get the specialized care they urgently need. With U.S. cases expected to double by 2040, researchers warn that existing healthcare inequities will worsen without immediate action. “Research…

Brain stem cell transplant patients may be able to take milder drugs

Parkinson’s disease patients who receive donor-derived brain stem cell therapy may be able to avoid potent immunosuppressant drugs without showing signs of rejection, a study in Japan suggested. The Phase 1/2 trial (jRCT2090220384) tested transplants of dopamine-producing precursor cells made from induced pluripotent stem cells (iPSCs) — stem…